Format

Send to

Choose Destination
Haematologica. 2007 Dec;92(12):1691-4.

Rituximab therapy for childhood Evans syndrome.

Author information

1
Assistance Publique-Hôpitaux de Paris, Service d'Hématologie-Oncologie Pédiatrique, Hôpital Robert Debré, Paris, France. brigitte.badermeunier@rdb.ap-hop-paris.fr

Abstract

The safety and efficacy of rituximab have been retrospectively assessed in 17 children with Evans syndrome. Patients received 4 or 3 weekly doses of rituximab (375 mg/m(2) per dose) associated with prednisone, alone (14 patients) or associated with other immunosuppressive drugs. Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted in 11 of them with a mean follow-up of 2.4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively.

PMID:
18055994
DOI:
10.3324/haematol.11540
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center